Sorry, you need to enable JavaScript to visit this website.

This website is intended for healthcare professionals in KSA and UAE only.

The content provided is developed in accordance with local regulations and may not be applicable or compliant in other regions.

This website is intended for healthcare professionals in KSA and UAE only.
 The content provided is developed in accordance with local regulations and may not be applicable or compliant in other regions.

Icon Search
hamburguer menu

Search results

hamburguer menu
Home

Home

/

Products

/

Engage Academy

/

Understand the funding process for KAPRUVIA®

Understand the funding process for KAPRUVIA®

Overview


November 2024

Watch this video, where Dr Keiran McCafferty explains how KAPRUVIA® is funded by NHS England and provides guidance on the Blueteq process

This webinar is CPD accredited

Download the certificate here once completed.

UK-DFK-2400103 (V2.0)

Key Timestamps


Please use the navigation at the bottom of the video to move easily to different chapters

0:00:05

Chapter 1 - Introduction

0:00:05

Chapter 2 - Agenda

0:01:20

Chapter 3 - What is CKD-associated pruritis? Symptoms, impact on patient pathophysiology

0:12:35

Chapter 4 - Screening, diagnosis, monitoring and treatment

0:25:25

Chapter 5 - Patient case studies

0:47:48

Chapter 6 - Prescribing information and close

Related Episodes

Adverse events should be reported. Reporting forms and information for United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma Ltd.
Tel: +44 1276 853633. E-mail: medicalinfo_UK@viforpharma.com

Stay informed

Register with Vifor Pharma for the latest releases. This will include promotional content

Register
Arrow right icon

Products

Explore CSL Vifor medicines & products

View Products
Arrow right icon